Tonix Pharmaceuticals Secures $20 Million Funding to Advance Fibromyalgia Treatment and Pipeline Development
核心洞察
Tonix Pharmaceuticals (搜索) completed a $20 million registered direct offering with Point72 (搜索), selling 615,025 shares at $16.26 per share to fund commercialization and development activities.
The company will use proceeds to support its marketed fibromyalgia (搜索) treatment TONMYA (搜索), the first FDA-approved prescription medicine for fibromyalgia in over 15 years.
Tonix's diverse pipeline includes treatments for central nervous system disorders, immunology, rare diseases, and infectious diseases, with several candidates in Phase 2-ready status.
Tonix Pharmaceuticals (搜索) Holding Corp. has successfully completed a $20 million registered direct offering with Point72 (搜索), providing crucial funding to advance the commercialization of its breakthrough fibromyalgia (搜索) treatment and support its expanding development pipeline. The biotechnology company sold 615,025 shares of common stock at $16.26 per share, with the offering expected to close on December 30, 2025.
The funding comes at a pivotal time for Tonix, which markets TONMYA (搜索), a first-in-class, non-opioid analgesic medicine for treating fibromyalgia (搜索) in adults. TONMYA represents a significant therapeutic advancement, being the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. The chronic pain condition affects millions of adults, highlighting the substantial unmet medical need that TONMYA addresses.
Comprehensive Product Portfolio
Beyond TONMYA (搜索), Tonix maintains a robust commercial portfolio that includes two treatments for acute migraine (搜索) in adults: Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). The company's strategic focus on commercializing these marketed products will benefit directly from the new funding.
The company's development pipeline spans multiple therapeutic areas, with particular emphasis on central nervous system disorders, immunology, immuno-oncology, rare diseases, and infectious diseases. TNX-102 SL, the investigational form of TONMYA (搜索), is currently being developed for additional indications including acute stress reaction (搜索) and acute stress disorder (搜索) under an Investigator-Initiated IND at the University of North Carolina in the OASIS study, funded by the U.S. Department of Defense (搜索).
Advanced Pipeline Candidates
Tonix's immunology portfolio features TNX-1500, a Phase 2-ready Fc-modified humanized monoclonal antibody targeting CD40-ligand (搜索) (CD40L (搜索) or CD154 (搜索)). This candidate is being developed for preventing allograft rejection and treating autoimmune diseases, representing a significant opportunity in the transplant and autoimmunity markets.
In rare diseases, the company is advancing TNX-2900, an intranasal oxytocin formulation potentiated with magnesium for Prader-Willi syndrome (搜索). This program is expected to initiate a potential pivotal Phase 2 study in 2026, marking a critical milestone in addressing this rare genetic disorder.
The infectious disease portfolio includes several notable candidates: TNX-801, a vaccine in development for mpox (搜索) and smallpox (搜索); TNX-4800 (搜索), a Phase 2-ready long-acting humanized monoclonal antibody for seasonal prevention of Lyme disease (搜索); and TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 (搜索). TNX-4200 is supported by a contract with the U.S. Department of Defense (搜索)'s Defense Threat Reduction Agency (搜索) worth up to $34 million over five years for preventing or treating high lethality infections in military personnel.
Strategic Financial Position
TD Cowen (搜索) served as the sole placement agent for the offering, with A.G.P./Alliance Global Partners (搜索) acting as financial advisor. The offering was conducted under an effective shelf registration statement previously filed with the Securities and Exchange Commission, demonstrating Tonix's established regulatory framework for capital raising activities.
The company intends to allocate the net proceeds toward three primary areas: funding the commercialization of its marketed products, advancing its product development pipeline, and supporting general working capital and corporate purposes. This strategic allocation reflects Tonix's dual focus on maximizing revenue from existing products while investing in future growth opportunities.
Tonix operates a state-of-the-art infectious disease research facility in Frederick, Maryland, providing the infrastructure necessary to support its diverse development programs. The facility enhances the company's capabilities in advancing its infectious disease portfolio, particularly given the strategic importance of its Department of Defense contracts.